Intestinal cancer
Therapeutic area
Gastroenterology
Rare disease
No
- Definition
- A malignant neoplasm involving the intestine
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Intestinal cancer
- Therapeutic area
- Gastroenterology
- intestinal cancer
- bowel cancer
- cancer of intestine
- cancer of the intestine
- intestinal neoplasms, malignant
- intestinal tumors, malignant
- intestine cancer
- malignant intestinal neoplasm
- malignant intestinal neoplasms
- malignant intestinal tumor
- malignant intestinal tumors
- malignant intestinal tumour
- malignant intestinal tumours
- malignant intestine neoplasm
- malignant intestine tumor
- malignant intestine tumour
- malignant neoplasm of intestine
- malignant neoplasm of the intestine
- malignant tumor of intestine
- malignant tumor of the intestine
- malignant tumour of intestine
- malignant tumour of the intestine
- Severity
- Severe
- Gastroenterology
- Oncology
Sources for recorded values
- MONDO ID
- MONDO:0005814
- Parent condition
- MONDO:0002516
Related records
Broader conditions (13)
- Cancer
- Cancer or benign tumor
- Digestive system cancer
- Digestive system disorder
- Digestive system neoplasm
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Human disease
- Intestinal disorder
- Intestinal neoplasm
- Neoplasm
- Neoplastic disease or syndrome
Narrower conditions (140)
- Adenosquamous colon carcinoma
- Ampulla of vater adenocarcinoma
- Ampulla of vater adenosquamous carcinoma
- Ampulla of vater cancer
- Ampulla of vater clear cell adenocarcinoma
- Ampulla of vater mucinous adenocarcinoma
- Ampulla of vater small cell neuroendocrine carcinoma
- Ampulla of vater squamous cell carcinoma
- Ampullary signet ring cell adenocarcinoma
- Anal canal adenocarcinoma
- Anal canal cancer
- Anal canal carcinoma
- Anal canal carcinoma in situ
- Anal canal neuroendocrine neoplasm
- Anal canal Paget disease
- Anal canal squamous cell carcinoma
- Anal carcinoma
- Anal gland adenocarcinoma
- Anal margin basal cell carcinoma
- Anal margin carcinoma
Trials (100)
- A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
- A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC
- A Prospective, Multicenter Randomized Controlled Study of the Application of Preoperative FOLFOXIRI Chemotherapy Combined With Lateral Lymph Node Dissection in Low- and Medium-lying Rectal Cancer With Lateral Lymph Node Metastasis
- A Retrospective Cohort Study for Main Postoperative Complications After SARS-CoV-2 Infection
- A Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer
- A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC
- A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab
- A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
- A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer
- A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
- A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
- A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)
- A Study to Evaluate the Safety and Efficacy of the Use of ME-APDS During Colonoscopy
- Accuracy of Detection Using ENdocuff Optimisation of Mucosal Abnormalities
- Adoptive Cell Therapy Plus Chemotherapy and Radiation After Surgery in Treating Patients With Colorectal Cancer
- An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate (Arfolitixorin) and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer
- An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer
- Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients
- Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C)
Drugs in development (2)
- Artesunate Phase 2
- Imatinib Phase 3